Hexarelin Mechanism of Action — Research Reference

Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide GHS analogue. It is one of the most potent GH-releasing peptides on a per-dose basis and is uniquely cited in cardioprotective and cardiac-remodelling research because of a secondary receptor target.

Receptor Targets

Hexarelin binds two receptors with research-relevant affinity:

1. GHS-R1a (ghrelin receptor) — primary pituitary target driving GH release.
2. CD36 (scavenger receptor B2) — expressed on cardiac myocytes, macrophages, and endothelial cells; mediates the cardioprotective effects observed in ischemia-reperfusion models.

Signal Transduction

Pituitary GH release follows the canonical GHS-R1a pathway (Gαq/PLC/Ca²⁺ + Gαs/cAMP/PKA). The CD36 arm activates distinct cardiac signalling — modulation of fatty-acid uptake, anti-apoptotic Akt phosphorylation, and reduction of post-ischemic infarct size in published rodent studies.

Pharmacokinetics

Subcutaneous hexarelin produces a high-amplitude GH pulse peaking near 30 minutes with a half-life of approximately 70 minutes — longer than ipamorelin, GHRP-2, or GHRP-6. The 2-methyl modification on D-Trp confers exceptional peptidase resistance.

Cortisol and Prolactin

Hexarelin elevates cortisol and prolactin more than ipamorelin and at least as much as GHRP-2 in published comparative work. Chronic dosing studies also report receptor desensitization that progressively blunts the GH response, an effect more pronounced than with other GHRPs.

Cardioprotective Research

Hexarelin's CD36-mediated effects produce reductions in infarct size and preserved cardiac function in rodent ischemia-reperfusion models — these endpoints persist in GH-deficient and hypophysectomized animals, confirming the cardiac signal is independent of the GH/IGF-1 axis.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.

References

1. Deghenghi R, Cananzi MM, Torsello A, et al. GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 1994;54(18):1321–1328.
2. Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844–849.
3. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45–53.